11.32

2.58% -0.30

After Hours: 11.32

Nevro Corp (NVRO)

Overview News Price History Option Chain Discussions Forecast Stock Split

Nevro Corp stock is currently priced at $11.32, with a 24-hour trading volume of 280.66K. It has seen a -2.58% decreased in the last 24 hours and a -16.58% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $11.82 pivot point. If it approaches the $11.29 support level, significant changes may occur.

Previous Close:

$11.62

Open:

$11.55

24h Volume:

280.66K

Market Cap:

$415.23M

Revenue:

$425.17M

Net Income/Loss:

$-92.21M

P/E Ratio:

1,132.00

EPS:

0.01

Net Cash Flow:

$-67.42M

1W Performance:

-6.21%

1M Performance:

-16.58%

6M Performance:

-25.28%

1Y Performance:

-67.27%

1D Range:

$11.26

$11.75

52W Range:

$11.26

$34.16

Nevro Corp Stock (NVRO) Company Profile

Name

Nevro Corp

Sector

Healthcare (1199)

Industry

Medical Devices (158)

Phone

650-251-0005

Address

1800 Bridge Parkway, Redwood City, CA

Employee

676

Twitter

@Nevro_HF10

Next Earnings Date

2024-05-23

Latest SEC Filings

NVRO's Discussions on Twitter

Nevro Corp Stock (NVRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-21-23	Downgrade	Canaccord Genuity	Buy → Hold
Jul-19-23	Initiated	Robert W. Baird	Neutral
May-31-23	Initiated	RBC Capital Mkts	Outperform
May-15-23	Upgrade	Oppenheimer	Perform → Outperform
Apr-14-23	Initiated	Mizuho	Neutral
Jan-17-23	Downgrade	Citigroup	Buy → Neutral
Jan-06-23	Downgrade	Piper Sandler	Neutral → Underweight
Dec-20-22	Upgrade	Canaccord Genuity	Hold → Buy
Dec-12-22	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-12-22	Initiated	Jefferies	Underperform
May-05-22	Upgrade	Citigroup	Neutral → Buy
Apr-13-22	Resumed	Truist	Hold
Apr-06-22	Initiated	Wolfe Research	Underperform
Mar-02-22	Resumed	BofA Securities	Underperform
Jan-07-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-06-21	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-09-21	Downgrade	Truist	Buy → Hold
Aug-05-21	Downgrade	Canaccord Genuity	Buy → Hold
Aug-05-21	Downgrade	Citigroup	Buy → Neutral
Aug-05-21	Downgrade	Piper Sandler	Overweight → Neutral
Aug-05-21	Downgrade	Wells Fargo	Overweight → Equal Weight
Aug-05-21	Downgrade	William Blair	Outperform → Mkt Perform
Jul-09-21	Downgrade	Redburn	Buy → Neutral
Jul-06-21	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-02-21	Initiated	Piper Sandler	Overweight
Oct-23-20	Initiated	Guggenheim	Buy
Sep-02-20	Initiated	Robert W. Baird	Outperform
Jun-08-20	Upgrade	UBS	Sell → Neutral
Mar-05-20	Initiated	Citigroup	Buy
Feb-26-20	Upgrade	Canaccord Genuity	Hold → Buy
Jan-08-20	Initiated	SunTrust	Buy
Jan-06-20	Downgrade	Oppenheimer	Outperform → Perform
Nov-07-19	Upgrade	Oppenheimer	Perform → Outperform
Oct-22-19	Initiated	Oppenheimer	Perform
Mar-20-19	Upgrade	BofA/Merrill	Neutral → Buy
Mar-20-19	Upgrade	Wells Fargo	Market Perform → Outperform
Nov-28-18	Initiated	UBS	Sell
Nov-07-18	Downgrade	BofA/Merrill	Buy → Neutral
Nov-06-18	Downgrade	JP Morgan	Overweight → Neutral
Nov-06-18	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Oct-19-18	Downgrade	Goldman	Neutral → Sell
Jul-02-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-08-18	Reiterated	Canaccord Genuity	Buy
May-08-18	Downgrade	Northland Capital	Outperform → Market Perform
May-08-18	Downgrade	Wells Fargo	Outperform → Market Perform

View All

Nevro Corp Stock (NVRO) Latest News

Nevro Corp Stock (NVRO) Financials Data

Nevro Corp (NVRO) Revenue 2024

NVRO reported a revenue (TTM) of $425.17 million for the quarter ending December 31, 2023, a +4.63% rise year-over-year.

Nevro Corp (NVRO) Net Income 2024

NVRO net income (TTM) was -$92.21 million for the quarter ending December 31, 2023, a -3,173% decrease year-over-year.

Nevro Corp (NVRO) Cash Flow 2024

NVRO recorded a free cash flow (TTM) of -$67.42 million for the quarter ending December 31, 2023, a -493.53% decrease year-over-year.

Nevro Corp (NVRO) Earnings per Share 2024

NVRO earnings per share (TTM) was -$2.57 for the quarter ending December 31, 2023, a -25,600% decline year-over-year.

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.